HCV News Digest
Senator: Cut Medicaid for hepatitis C patients who drink alcohol, go off meds
TOPEKA – Medicaid recipients being treated for hepatitis C who drink alcohol or go off their medication would lose coverage under a recommendation passed by a legislative panel Tuesday.
Research shows hepatitis C is associated with increased risk of heart disease
The researchers examined the records of approximately 25,000 patients. They compared the rate of heart attacks in patients with and without hepatitis C infection. They found that patients with active hepatitis C infection had a 59 per cent higher chance of developing a heart attack related event compared to patients without hepatitis C, even though they had the same cardiac risk factors like hypertension and diabetes.
The prevalence of mixed genotype infections in Polish patients with hepatitis C.
The obtained results showed that infection with mixed HCV genotypes in Polish patients with hepatitis C, is uncommon. Selective elimination of genotypes 3a and 4a after therapy confirms the genotype 1b greater resistance to treatment. In the context of new anti-HCV drug development further investigations are needed to determine the clinical importance of mixed hepatitis C infection. Abbreviated title: Mixed genotype infections with hepatitis C in Polish patients. Mixed genotype hepatitis C infections.
Consumer advocates targeting drug gouging in 2016
That increase, the steepest since 2001, was fueled primarily by new cancer therapies, drugs to treat complex diseases like multiple sclerosis and rheumatoid arthritis, and a pair of medicines developed by Gilead Sciences of Foster City to treat ...
The Same Pill That Costs $1,000 in America Sells for $4 in India
The sofosbuvir rivals are aggressive about expanding the customer base by making the pills affordable and diagnosis easier. Dr. Reddy’s, for example, set up a venture with lender Arogya Finance to offer no-interest loans for patients, and Abbott Laboratories worked with French medical equipment company Echosens SAS to supply Indian hospitals with 13 ultrasound machines that determine the level of fibrosis, or hardening, without a liver biopsy.
Hep Savvy: All baby boomers should get screened for Hepatitis C
The price keeps falling for a superstar Gilead hepatitis C drug in India
Gilead licensed 11 Indian firms to make generic versions of Sofosbuvir, and they sealed marketing deals with others, making the competition extremely fierce
A quarter of people with HCV initially refused access to sofosbuvir/lepidasvir ...
Because of this high cost, insurer authorisation often requires that people have advanced fibrosis (F3 or above) or cirrhosis. Investigators from Yale Liver Center wanted to see how many people with HCV were obtaining authorisation for therapy with SOF ...
Hep C patient goes offshore for cure
India - Govt. adds Cancer, HIV, Hepatitis C to list of essential medicines
Why Food Poisoning Outbreaks Appear To Be On The Rise
Listen to the Story
Biocon launches generic version of Hepatitis C drug in India
The Times of India
46 mins ago - Biopharmaceutical company Biocon said it launched a generic version of Gilead Lifesciences' hepatitis C drug, Harvoni, in India.
CDC finds US alcohol poisoning and cirrhosis 'deaths hit record high'
Hepatitis C Linked to Parkinson's Disease
New research offers 'well-documented evidence' of a link between the hepatitis C virus and risk for Parkinson's disease.
Medscape Medical News,
Abstract - published in the journal Neurology Dec 23 2015.
Related - Hepatitis C Virus Infection: A Risk Factor for Parkinson's Disease - Journal of Viral Hepatitis Oct 2015
Expert Perspectives: Latest Clinical Update on Current and Emerging HCV Regimens
Dr. Mark Sulkowski and Dr. David Wyles provide their expert perspective on management of patients with chronic HCV. The webcast features an interactive discussion on recent clinical developments with current HCV treatments, an update on late-stage HCV treatment regimens and evidence-based recommendations on the management of HCV mono-infected and HIV/HCV co-infected patients.
Australia bets $1B on pricey hep C drugs in broad effort to eradicate the disease
Australia is earmarking $1 billion to subsidize Gilead's Sovaldi and Harvoni, along with Bristol's Daklinza--as well as Pendopharm's ribavirin tablets, Ibavyr--for all hep C patients, regardless of their age or how they acquired the disease, Sky News ...
Improved Fibrosis Staging in Patients With Liver Disease
Liver International, December 23, 2015
A Once-daily NS5A Inhibitor in Patients With Genotype 1-4 HCV
Journal of Viral Hepatitis, December 18, 2015
New Drug Review 2015
U.S. Pharmacist, December 18, 2015
New, better, cheap Hep C drugs to help patients, attract foreigners
Hindustan Times - 3 hours ago
The launch of new generic oral antiviral drugs to treat Hepatitis C by major pharmaceutical companies would help reduce considerably the cost of the treatment of the disease, helping more than 12 million affected Indians, and attract foreigners to come ...
HCV Next: HCV and the Gastroenterologist, Exciting Real-World Data, New Regimens Emerge
Monroe County amid hepatitis C epidemic
Local Impact: Hepatitis C and Medicaid spending
PR Newswire (press release) - 19 hours ago
WASHINGTON, Dec. 22, 2015 /PRNewswire-USNewswire/ There has been a lot of discussion about the cost of new hepatitis C treatments to state Medicaid programs.
CMS Shares Highest $ Medicare Drugs of 2014
Hep C drug accounts for greatest share of Medicare drug spending
CMS launches online Medicare prescription drug spending resource
The Centers for Medicare and Medicaid Services launched an interactive resource with information about Medicare spending on prescription drugs, the agency announced in a press release.
Hepatitis C genotype 4: The past, present, and future.
Direct-acting antivirals may significantly improve treatment outcomes in HCV- GT-4, but use of these agents in countries endemic for HCV-GT-4 is currently precluded by the very high costs. A new hepatitis C vaccine from GlaxoSmithKline has shown promise in early clinical tests, prompting strong and broad immune responses. Another Egyptian clinical trial in the field of HCV vaccination: Clinical Trials phases I and II, started on March 2011. ClinicalTrials.gov Identifier NCT01718834.
Think before you ink, public health warns - The Weekly News
Many Patients on New HCV Medications at Risk of Drug-Drug Interactions
Hepatitis C in the Era of Direct-acting Antivirals
High Cost of Our Medications and What Can Be Done About It
We live in a capitalistic society but how much is too much when the decisions regarding life and death or at least prolonging life come into question. Americans spend more on their medications than any other country.
N.H. plans to start tracking new cases of hepatitis C
CONCORD, N.H. (AP) — Public health officials in New Hampshire say they plan to begin tracking cases of hepatitis C amid growing concerns regarding the state's opiate epidemic and the practice of sharing needles.
New medicine for Hepatitis C treatment launched
During the conference, two new drugs were launched for treatment of Hepatitis C disease at affordable price. (Source: The Economic Times Healthcare and Biotech News)
You cannot argue against the science on hepatitis C ... or vaccination
Hepatitis C Health: Ten Tips for the Holidays
Abbott and UC San Francisco Discover New Virus is Linked to Hepatitis C
Abbott and University of California San Francisco (UCSF) published research identifying a newly discovered human virus, known as human pegivirus 2 (HPgV-2), and proving it is found among some patients with hepatitis C (HCV).
Scientists discover a potential treatment for cirrhosis
A study by IRB Barcelona and IDIBAPS reveals a therapeutic target to prevent the development of the many abnormal blood vessels that cause gastrointestinal bleeding—the main complication in cirrhosis
Time to do away with the FDA
For individuals suffering from hepatitis C, a blood-borne virus causing liver inflammation, life can be difficult. For 70-85 percent of those with the virus, the condition is chronic..
Fighting liver fibrosis, the wound that never heals
Scientists at the Salk Institute have identified a drug that halts this unchecked accumulation of scar tissue in the liver. The small molecule, called JQ1, prevented as well as reversed fibrosis in animals and could help the millions of people worldwide affected by liver fibrosis and cirrhosis, caused by alcoholism and diseases like hepatitis. These results were published in PNAS the week of December 7, 2015.
The Hepatitis C Revolution Part 1
This review article discusses novel hepatitis C virus treatment options in hopes to clarify best available evidence for clinicians treating patients with HCV.
December 09, 2015
Sofosbuvir with velpatasvir in treatment-naive noncirrhotic patients with genotype 1 to 6 hepatitis C virus infection
Grazoprevir/elbasvir cures more than 90% of people with HIV/HCV co-infection
Merck's grazoprevir/elbasvir combination cured 93% of people with HIV and hepatitis C co-infection, was well-tolerated and did not appear to interact with antiretrovirals, according to final results from the C-EDGE Co-infection study presented at the ...
Activists dressed as Gilead butchers greeted participants at the European Conference on HIV and Hepatitis Coinfection
On the morning of Thursday 10th December 2015, a public action targeted specifically at big pharma profiteering from the lives of people with hepatitis C happened in central London. Activists dressed as Gilead butchers greeted participants as they arrived at the European Conference on HIV and Hepatitis Coinfection
Statin use may reduce risk for cirrhosis in patients with HCV
The use of statin therapy among patients with hepatitis C virus infection reduced their risk for developing cirrhosis, according to published findings.
Current trends indicate a rise in cirrhosis, HCC incidence
December 7, 2015
SAN FRANCISCO — According to data presented at The Liver Meeting 2015, a national retrospective study of Veterans Affairs patients showed increasing incidence…
HCV genotype 3: a wolf in sheep’s clothing
Moving on to the third point, and so concluding this topic, it is necessary to understand the clinical implications of the different HCV G3 subtypes (in other words, immunity, inflammation, prognosis, response to DAAs). This is something we already known for HCV G1a and 1b. At least 10 HCV G3 subtypes have been described so far. Are some of these HCV G3 subtypes able to evade the immune response? Can we expect the same SVR for different subtypes? The correct identification of HCV G3 subtypes would probably be necessary because they are crucial in clinical trials evaluating the new DAAs. No data have so far stratified the response of HCV G3 to the new DAAs, which could be an essential issue that requires further investigation.
St. Louis VA says it’s not turning away any patients with Hepatitis C seeking expensive prescriptions
The Impact Of New Hepatitis C Drugs On National Health Spending
December Hepatitis Newsletters: Highlights From AASLD 2015 - Treating Genotype 3, Cirrhosis and Liver Cancer
European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Sofosbuvir/Velpatasvir for the Treatment of Hepatitis C
If Approved, SOF/VEL Would be the First All-Oral, Pan-Genotypic Single Tablet Regimen for Chronic HCV in Europe
SOF/VEL Granted an Accelerated Assessment by the European Medicines Agency
Bone disorders in children and adolescents with chronic HCV infection.
Although several studies have demonstrated a higher incidence of bone disorders in HCV-infected adults, the bone turnover alterations occurring in children and adolescents with chronic hepatitis C has not been thoroughly focused yet. We performed a study on a cohort of 30 HCV infected caucasian children and adolescents to assess the prevalence of osteodystrophy and evaluate a possible prophylactic and therapeutic approach.
Failure with All-oral DAA Regimens: Real-world experience from the TRIO Network. Academic and community treatment of a real-world, heterogeneous population -
from Jules: of note is TRIO finding of lower SVR rates when patients were treated outside the Guidelines, see slides below as to how but it included not using Rbv with Harvoni in cirrhotics, not using Rbv along with Viekira Pak, and appears not using Viekira Pak.Rbv appropriately. Also note the differences in SVR between Harvoni with & without Rbv which may be due to treating outside the Guidelines when Rbv is recommended.
U.S. salmonella outbreak across nine states investigated
ATLANTA A salmonella outbreak that has sickened 11 people in nine states could be linked to a line of nut butter spreads that were recalled this week, a U.S. health agency said on Thursday.
Flu Vaccine Keeps Taking Hits, Still the Best We’ve Got — Don’t Stop “Belivin'” [sic]
Blame the System, not Gilead - Bloomberg Gadfly
48 mins ago - The Senate Committee on Finance report on Gilead's pricing of its blockbuster hepatitis C drugs Sovaldi and Harvoni is ominous, promising dark revelations of ...
VA Doctor Invented Hepatitis C Cure, Sold It For $400 Million Profit
December 3, 2015 by Benjamin Krause
Apparently, Dr. Raymond Schinazi, a VA doctor since 1983, founded a company named Pharmasset and led the scientific team that discovered sofosbuvir while working at VA. That is the substances used in current hep C pill treatments.
Gilead’s Pricing of Hepatitis C Drugs Investigated by Senate
Clinical Outcome in Post-transplant Hepatitis C Recurrence
Liver International, December 2, 2015
Hepatitis C Virus Treatment in the Real World
Gut, December 1, 2015
HCV Most Common Infectious Cause of Death, Yet Still Underestimated
Publish Date: Wednesday, December 02, 2015
Hepatitis C infection causes more deaths than HIV, hepatitis B, and tuberculosis combined.
Anti-viral medications for hepatitis C to cut infection by 80 per cent
NEW YORK: Recently approved anti-viral medications for hepatitis C could reduce the prevalence of the blood-borne infection by more than 80 percent, researchers have estimated.
AbbVie Announces FDA Acceptance of NDA for VIEKIRA PAK®
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced its New Drug Application (NDA) has been accepted by the U.S. Food and Drug Administration (FDA) for a once-daily, fixed-dose formulation of the components of VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets). VIEKIRA PAK is an all-oral, interferon-free treatment approved with or without ribavirin (RBV) in the United States for patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with compensated cirrhosis. VIEKIRA PAK is not for people with decompensated cirrhosis.
Australians must be given access to this life-saving Hepatitis C treatment
Wyden-Grassley Findings Could Punish Gilead
Recent findings from the Wyden-Grassley report suggest Medicare spent over $8B on Sovaldi and Harvoni prior to rebates.
Wyden-Grassley suggests Gilead's HCV pricing was based on maximizing revenue and not driven by R&D costs.
Given Medicare's large volume purchases, it may have the power to demand bigger HCV discounts....
VA can't afford drug for veterans suffering from hepatitis C
On Tuesday, a Senate report found Gilead Sciences, which makes a cure for a fatal form of hepatitis, is more interested in profits than patients. The cure was invented under the leadership of a celebrated doctor in the Department of Veterans Affairs, but at $1,000 a pill, even the VA can't afford to save the lives of veterans who need it.
Dr. Raymond Schinazi founded the company, Pharmasset, and led the scientific team that discovered sofosbuvir. He also works for the Department of Veterans Affairs and has since 1983.
He said he is only a 7/8th's government employee. So what he does with his remaining time is up to him.
He said he is spending less than 1/8th of his time on private companies.
"Well, even less than that. I'm very efficient," he said
Sovaldi Investigation Finds Revenue-Driven Pricing Strategy Behind $84,000 Hepatitis Drug
A report released Tuesday by US Senators Ron Wyden and Charles Grassley claims that Gilead Sciences priced the hepatitis C treatments Sovaldi (sofosbuvir) and Harvoni (ledipasvir/sofosbuvir) with the sole goal of maximising revenue. The report was based on an investigation of 20 000 pages of internal company documents, dozens of interviews with health care experts and data from Medicaid programmes in all 50 states and the District of Columbia.
“Gilead pursued a calculated scheme for pricing and marketing its Hepatitis C drug based on one primary goal, maximizing revenue, regardless of the human consequences. There was no concrete evidence in emails, meeting minutes or presentations that basic financial matters such as R&D costs or the multi-billion dollar acquisition of Pharmasset, the drug’s first developer, factored into how Gilead set the price....
Enhanced treatment for hepatitis C could cut prevalence by 80%
Novel antiviral therapies for hepatitis C could reduce the prevalence of the blood-borne infection by more than 80%, according to an analysis by Yale researchers.
Veterans can reduce impact of hepatitis C
The American Liver Foundation believes part of that good care for veterans is making sure they get examined for potential liver diseases, especially the chronic hepatitis C virus, or HCV.
STAT-Harvard poll: Dismayed by drug prices, public supports Democrats' ideas
Another 13 percent support negotiations for just high-cost drugs for illnesses such as hepatitis C or cancer. But there are also signs that the strong public support may be less about a specific proposal and more about the general idea that the ...
Blue Cross Sued Over Denying Patients Hepatitis C Treatment
AJMC.com Managed Markets Network
New hepatitis C drugs may have high cure rates, but they come at a high price—one that insurers might not be willing to pay.
Real life Dallas Buyers Club operation helps hepatitis C patients with free drugs
Veterans Journal: VA expands treatment program for hepatitis C, other illnesses caused by military service
Cost, other barriers keep some hepatitis patients from treatment
Research: Supervised injection facilities would be cost-effective in Toronto and Ottawa
Hepatitis C cases rise in Bay County
Hepatitis C cure may cost as low as Rs 67k
The Five: Pan-Genotypic Drugs —By Alan Franciscus
Functional Human Liver Cells Grown in the Lab
Post-AASLD, Gilead's lead in hep C looks as solid as ever: Analysts
Keeping Up With Rapid Advances in Hepatitis C Treatment
Hepatitis C - NICE publishes final drug recommendations for the treatment of four separate medical conditions
Trinity Scientists Homing in on New Hepatitis C Vaccine
HCV: 4 Weeks Too Short for Treatment With New Drugs
AbbVie's TECHNIVIE™ Receives Health Canada Approval for Genotype 4 Chronic Hepatitis C Infection
AASLD: Hepatitis C Disease Burden in the United States in 2015 and Beyond
Incidence and Determinants of Denial of DAA Therapy by Type of Insurance During the First 6 Months of the Modern HCV Treatment Era
Expensive drugs that cure hepatitis C are worth the cost, even at early stages of liver fibrosis
Hepatitis C Highlights of the 2015 Liver Meeting
Exclusive HCV Interview: Lucinda K Porter, RN
Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: Myth or reality?
Daklinza(Daclatasvir): Bristol-Myers Lets Low-Income Countries Copy Hepatitis C Pills
Platelets promote the liver's regeneration process following surgery
Galectin Therapeutics - Developing New Treatments For Fibrosis and Cirrhosis
ASTRAL-2: Sovaldi/velpatasvir bests standard therapy in HCV genotype 2
Liver fibrosis improves after successful treatment for hepatitis C
Hepatitis C Cure Often Leads to Improvement in Liver Health
Daklinza & Sovaldi Better Treats Those With HIV & HCV
High Genotype 2 and 3 Hep C Cure Rates for New AbbVie Combo
Near-Perfect Results for New AbbVie Hep C Combo in Genotype 1s
Clinicians Have Multiple First-line Options for Treating HCV; Challenge is Implementation: all patients have right to be treated
Sofosbuvir plus Velpatasvir for Chronic Pangenotypic HCV Infection: Phase III Results
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
It's time to stop stigmatizing Hepatitis C patients and cover their treatment
Short-Course Triple HCV Tx Has Promise in Cirrhosis
Watch Independent Expert Review on AASLD 2015: Discussion on HCV therapeutic options and developments
Watch Patients Treated For Hepatitis C: Studying possible regression in cirrhosis/ fibrosis
Reducing HCV disease burden may be possible within 6 years
US calls for a ban on advertising prescription drugs
Ledipasvir/Sofosbuvir Produces Sustained Virologic Rate in Patients With Hepatitis C Genotype 1 and Cirrhosis: Presented at Liver Meeting
AASLD 2015 - The Risk of Developing Liver Cancer Even After Being Cured from Hepatitis C
Nations Awaiting Price Break in HCV Drugs
HCV: Making it Rare in the US Will Cost $106 Billion, Study Finds
Treating HCV Patients Who Fail Direct-Acting Antivirals
NEJM EDITORIAL: Simple, Effective, but Out of Reach? Public Health Implications of HCV Drugs
Are Adult Doses of HCV Regimens Appropriate in Adolescents?
Elbasvir/grazoprevir effectively treats patients with compensated cirrhosis
SVR associated with improvement in fibrosis, cirrhosis
Liver Disease A Serious Concern in Veteran Population
Q&A With Melissa Harris From Bristol-Myers Squibb: Expanding Hepatitis C Treatment To New Genotypes And Populations VIDEO
AASLD 2015 - Merck Announces Results from Two Phase 2 Studies of Investigational Triple-Combination Chronic Hepatitis C Therapy
Janssen Presents New Data Assessing OLYSIO® (Simeprevir) in Combination with Sofosbuvir in Genotype 4 Infected HCV Patients In Egypt
Pharco Reports Ravidasvir with Sofosbuvir Achieved 100% Cure Rate for Non-Cirrhotic, Genotype 4 Patients
AASLD 2015: Sofosbuvir/ Velpatasvir + GS-9857 for 8 Weeks Cures Most Genotype 1 or 3 Hepatitis C Patients
ABBVIE Announces High SVR In Phase 2 studies With Pan-Genotypic Investigational Regimen ABT-493 AND ABT-530
Patient advocacy groups protest limits of Gilead's support program
Can Coffee Help Cut Risk of HCC Recurrence?
Weekend Updates: Series Of 5-minute Daily Clips From The Liver Meeting 2015
Gilead Highlight the Utility of Sofosbuvir-Based Hepatitis C Therapies at The Liver Meeting 2015
FDA - HARVONI (ledipasvir/sofosbuvir) label update
HCV NEXT November Issue - Pricing Pressures: How the Business of Medicine Affects the Price of Therapy
AASLD 2015 - Hepatitis C: an Effective Regimen for Genotype 3
HCV in Egypt: Success in Treating Genotype 4
Insurance Lagging on Paying for HCV Antivirals
HCV Antiviral Resistance a Challenge
Liver Transplant: Ribavirin Not Necessary to Prevent HCV Recurrence
Liver Transplant Lists Grow Shorter
Chinese Study Finds Cheaper, Shorter HCV Drug Regimen
Gilead Presents New Data at The Liver Meeting 2015 - Investigational Compounds for Chronic Hepatitis B and Liver Fibrosis
AASLD - AbbVie Announces New Data on VIEKIRA PAK®\
One-step test for hepatitis C virus infection developed by UC Irvine Health researchers
Medicaid denies half of prescriptions for new hepatitis C drugs
Conatus Pharmaceuticals Announces Selection of Late-Breaking Oral Presentation as Noteworthy Abstract to be Highlighted in AASLD President's Press Conference at AASLD Annual Meeting
FDA Approves New Indications for Harvoni®, Gilead's Once-Daily Single Tablet Regimen for Chronic Hepatitis C
As NJ’s heroin epidemic grows, potentially deadly hepatitis C spreads
Is cure of hepatitis C with medications possible?
The Latest Hepatitis C News at the Annual Liver Meeting
Best of the International Liver Congress 2015: Focus on Fatty Liver
Coffee Consumption Decreases Risks for Hepatic Fibrosis and Cirrhosis: A Meta-Analysis
This Is Why Hepatitis C Drugs Are So Expensive
Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012
Changes Afoot at The Liver Meeting
Knowns and unknowns of US drug pricing
$14 Million PCORI Research Grant Awarded to Montefiore and Einstein to Fund Hepatitis C Research
Faster, Cheaper Hep C Cures on the Horizon?
CMS Enters Pricey Hepatitis C Drug Debate
Template and white paper for State Insurance Commissioners re: HCV Tx Access
Addenbroooke's consultant hails drugs announcement for hepatitis patients a ...
UIS researchers studying Hepatitis C among homeless
Type 2 Diabetes Patients Fall Into Three Groups, Say Scientists
Antivirals May Reduce the Need for Recurrent Transplants in HCV
Grazoprevir, Elbasvir Combination Effective for Patients With Hepatitis C, Kidney Disease: Presented at Kidney Week
President of Malta presents €1.2 million worth of Hepatitis C medication to government
An Early Hepatitis C Thanksgiving Blessing
Information Update - Risk of Serious Liver Injury associated
with Hepatitis C Treatments: Holkira Pak and Technivie
Nov 2015 HCV Newsletter and Blog Updates
Gilead's Sovaldi Tied to Slow Heartbeat in Hepatitis C Patients
Therapy With Direct-Acting Antivirals for Genotype 3 Patients:
Interferon's Last Gasp? Commentary
Harvoni for Acute Hepatitis C
Interferon Makes a Comeback for Tough-to-Treat HCV
Innovative Calculator Tool Giving Insight into the Costs of Hepatitis C beyond Anti-Virals
Disease burden of chronic hepatitis C among immigrants
Find Way to Focus on Dietary Supplement Safety, Experts Say
Medicaid officials want to expand access to pricey hepatitis C drug
Weekend Reading: AASLD 2015 Key Abstracts and Treatment of HCV Genotype 3: Where are we now?
Gilead Submits NDA to U.S. FDA for Fixed-Dose Combination of Sofosbuvir/Velpatasvir for Treatment of All Six Genotypes of Hepatitis C
HCV News Digest
The Dark Side of Letting Insurance Payers Dictate Hepatitis C Treatment
Direct-Acting Antiviral Therapies Beneficial in HCV-MCS
Express Scripts to maintain availability of AbbVie's hep C drug
Baby boomers with HCV have low incidence of varices, PHG
NAFLD: An Emerging Epidemic with No Approved Treatment
Intercept Pharmaceuticals Announces Results of Phase 2 Trial of OCA in NASH Patients in Japan
Gilead Sciences Announces Third Quarter 2015 Financial Results
Scientists track hepatitis C roots in Scotland
Successful hepatitis C treatment lowers risk of death for people with HIV and HCV co-infection
Strategies for hepatitis C ‘treatment as prevention’ must address the concerns …
Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvir
Response to treatment in recently acquired hepatitis C virus infection
Grazoprevir-Elbasvir Effective for Hepatitis C in Advanced Chronic Kidney Disease
Drug Pricing: Public Health Implications | The Forum at HSPH
Hepatitis C increases risk of cardiovascular mortality
Risk of HCC in Chronic HCV Patients With New Onset Diabetes
Prevalence and Care for Hep C Varies Widely Across Continent
Viekira Pak and Technivie - FDA warns of serious liver injury risk with hepatitis C treatments
OCT/NOV 2015 American Liver Foundation Newsletter: Focus on liver cancer
AASLD - Benitec To Present Interim Data of TT-034 Phase I/IIa Study At Liver Meeting
Diabetes, Hypertension Raise Risk for Liver Cancer
NAFLD and Obesity: What Is the Mortality Risk?Studies find link between non-alcoholic fatty liver disease, higher death risk
Slower Fibrosis Progression Among Liver Transplant Recipients With Sustained Virological Response After Hepatitis C Treatment
My Fave Free Health Apps for Liver Disease
AbbVie's HOLKIRA PAK Now Reimbursed in all Four Atlantic Provinces
October Update- Upcoming and Recruiting Hepatitis C Clinical Trials
'Dallas Buyers' Club' for Hep C treatments under investigation
AASLD: Bristol-Myers To Present Data From Multiple Studies Of Difficult-To-Treat Chronic Hepatitis C Patients
Henry County monitoring uptick in Hepatitis C cases
Weill analysis finds high prevalence of hepatitis C
AASLD 2015: Late-breaking abstracts [PDF] are now available for download.
Merck to Present New Data on Investigational Chronic Hepatitis C Treatment Elbasvir/Grazoprevir at The Liver Meeting® 2015, Including Phase 3 Results in Selected Difficult-to-Treat Populations
Merck's Shorter-Treatment Hep C Drugs Work in Mid-Stage Trial
Researchers find possible link between marijuana, HCV
October print edition of HEALIO GASTROENTEROLOGY
Hep Blogs : Generic Hep C Treatment is Springing Up All Over by Greg Jefferys
Stanford addiction expert: “The country needs to spring into action” on heroin epidemic
CDC reports rising number of hepatitis C-related deaths
Produced in collaboration with hivandhepatitis.com
Many Eligible Elderly Patients Not Taking Statins
SGH Hep C cluster: Independent committee appoints 2 international experts
Cambodian on trial for infecting more than 100 with HIV
SVR improves overall survival, lowers risk of recurrence of HCC
Rising HCV -related mortality greater than all other infectious diseases.
Oral Direct-Acting Antivirals Safe, Effective in the Short Term for Treating Hepatitis C: Presented at ACG
Hep C: The Pan-Virals Are on the Way
Acetaminophen Recalled for Incorrect Strength Labeling
Sharon residents make marjuana dispensary pitch
Groundbreaking computer program diagnoses cancer in two days
Decentralized HCV Treatment is Effective!
NICE backs three hepatitis C meds, turns down Duchenne drug
Slide Show: Healthcare-Associated Hepatitis B and C Outbreaks
Predictors of hepatic flares in pregnant women with chronic hepatitis B
2015-2016 Influenza Season: Importance of getting vaccinated if you have HCV or underlying liver disease
All-oral interferon-free treatments: The end of hepatitis C virus story, the dream and the reality
Medicare Spending for Hepatitis C Cures Surges
Achillion Announces That Janssen Has Initiated a Phase 2a Study to Evaluate the Combination of AL-335, Odalasvir (ACH-3102), and Simeprevir for the Treatment of Genotype 1 Chronic HCV
NICE Recommends Daklinza (daclatasvir) for Treatment of Certain Patients With Chronic Hepatitis C Genotypes 1, 3 and 4
NICE announce criteria for access to Daklinza, Harvoni, Viekirax and Exviera
U.K. cost watchdog gives thumbs-up to Bristol-Myers' hep C drug
HBV obtained during childhood may lead to early death post-transplant
How insurance providers deny hepatitis C patients lifesaving drugs
HepQuant-STAT predicts HCV patients' risk for clinical outcomes
Advera: AbbVie's Viekira Pak riskier than Gilead's Harvoni for hep C
New October Publications - Parameters for Primary Care Physician HCV Treatment
Upsurge in HCV Deaths Despite New Treatments
Treatment Response in Sofosbuvir-Based Therapy of HCV
New hepatitis C treatments have excellent outcomes
Hepatitis C cases in county climb
Drug Interactions between TAF-Based Regimens and HCV Treatments in Coinfected Patients
October Newsletters: The Medicaid FFS formulary has added Daklinza and Technivie as non-preferred drugs for HCV.
Isoprene in Exhaled Breath May Be an Option for Diagnosing Fibrosis in Liver Disease
Indian Drugmakers Engineer Hep C Cocktails Impossible in West
Is Age A Consideration for Liver Transplant?
Australia could be world leader in Hepatitis C treatment: experts
Free medication for Hepatitis C - Icelandic state will provide medication for 1200 people
Dozens of co-workers are being screened for HIV and hepatitis after a nurse was found reusing a syringe to administer flu shots
WHO Decision to Recommend Treatment for All with HIV an Easy One — Now Comes the Hard Part
U.S. FDA Grants Priority Review For Daklinza (daclatasvir) sNDAs
FDA approved revisions to the Olysio (simeprevir) label to include dosing recommendations for the treatment of HCV/HIV-1 coinfection and to expand the indications and usage to include genotype 4 infection.
New all oral therapy for chronic hepatitis C virus (HCV): a novel long-term cost comparison
Singapore hospital says 4 renal patients died of hepatitis C infections ...
HEPATITIS C GENERALLY DOES NOT KILL QUICKLY
Results from Merck’s Phase 3 Study of HCV therapy with Elbasvir/Grazoprevir in Patients with Advanced CKD in Lancet
Treating 5 percent of hepatitis C patients with new drugs would reduce cost ...
iPhone app provides a window into patients' real-world experiences with hepatitis C
Leaders Must Work to Eradicate HIV and Hepatitis C
Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis
New STD Guidelines for 2015 - Medscape
Can the market fix healthcare costs?
New HCV NS5A inhibitor EDP-239 looks good in early studies, more evidence supports early hepatitis C treatment
Hepatitis C Untreated- NYU Researchers Find Serious Liver Damage in Mid- to Late-Adulthood Among People Who Inject Drugs
Health Benefits of Tea? Here’s What the Evidence Says
AASLD - The Liver Meeting® 2015 abstract supplement available online
Patients have mixed feelings about hepatitis drugs
HCV Weekend Reading - Diet, nutrition, physical activity, and liver cancer
Global Patterns of Hepatocellular Carcinoma Management From Diagnosis to Death
Gulf War Soldier infected with hepatitis C after being given tainted blood transfusion
Liver Cirrhosis Treatment May Curb Cerebral Edema
HCV Advocate Eblast: October 1, 2015
Hepatitis C: where are we now? The landscape
Recent HCV patients show more complications than decades prior
Searching for Sovaldi: Buying Generic Sofosbuvir in India: A Travel Journal
Malnutrition in cirrhosis increases morbidity and mortality
9 Things People with Hepatitis C Wish Their Doctors Would Do
IDWeek 2015: What to Expect
Groups ask Health Minister to put hepatitis C drugs on PBS
Gilead Sciences continues to produce new pharmaceuticals to treat hepatitis C, HIV
HCV Current Initiative: Addressing the National Epidemics of Prescription Opioid misuse and Hepatitis C through Unique Partnerships
The Future in Liver Medicine: The extinction of chronic viral hepatitis?
Long-Term Safety Of Medical Cannabis In The Treatment Of Chronic Pain
FDA grants orphan drug designation to BLU-554 for liver cancer.
Report: wide variance in Medicaid use of costly
Hepatitis and the Sustainable Development Goals: time for an end run
Cigarette smoking increases the risk of mortality from liver cancer
Cost-Effectiveness of Sofosbuvir-Based Treatments for HCV
Full Text: HCV targeting of patients with cirrhosis
AbbVie's VIEKIRAX Approved In Japan For Genotype 1 Chronic Hepatitis C
Treatment of Chronic HCV in Patients With Cirrhosis
Cell Death Discovery - Nature
Historical Path of Discovery of Viral Hepatitis
Diabetes and hepatitis C: a two-way association
Liver Enzymes Tell Tale in Hepatitis C Complications
Big data, Events, Health Costs, Health Policy, Medicine XPeter Bach on drug pricing: “A system so broken even a child could manipulate it”
TGIF Rewind: Big pharmaceuticals and the Hepatitis C drug trail dubbed a 'miracle cure
Two HCV Drugs to Be Discontinued
Most challenges to curing hepatitis C aren't medical
Interferon-based therapy still common for HCV among veterans
Conatus Announces emricasan Phase 2 study reduces liver portal hypertension predominantly due to NASH or HCV
Who gets hepatitis C drugs? Who pays?
Rational Drug Pricing
New Virus Similar To Hepatitis C Can Be Transmitted Through Blood Transfusions...
Common risk factors of fibrosis progression in chronic hepatitis C
An Algorithm to Predict HCC in Those With HCV and Cirrhosis
Prevalence of Cirrhosis in Hepatitis C Patients
Anemia—a Real Problem for Patients With IBD
Biotech stocks slide over prospect of price-controls
Gilead Announces SVR12 Rates from Four Phase 3 Studies Evaluating Fixed-Dose Sofosbuvir/Velpatasvir (GS-5816) Pan-Genotypic
Hepatitis C or No Hepatitis C, Get a Flu Shot
Evaluation of the regional nurse-supported hepatitis C shared care program in Western Australia: a mixed methods study
These New Expensive Drugs Could End The Hepatitis C
Hepatitis C Weekend Review
Psychosocial assessment and monitoring in the new era of non-interferon-alpha hepatitis C virus treatments
Study Shows Increase in Hepatitis C Rate Among Some HIV-Positive Men
Will The Next Hepatitis C Drugs Hit It Big?
Assessing cardiovascular risk in hepatitis C: An unmet need.
Hepatitis C-Salvage Study Grazoprevir and Elbasvir Plus Ribavirin: Final 24-week Follow-up Results
Novel plan to curb drug costs seeks candidates' attention
2015 Kelly Report: Health Disparities In America
What We Talk About When We Talk About Hepatitis C
Achillion Reports 100% SVR12 From Second Cohort of Patients in the Previously-Completed Six Week Phase 2 Trial Evaluating Odalasvir (ACH-3102) and Sofosbuvir for Genotype 1 HCV ("Proxy Study")
Health Canada proposes new liver damage labeling for acetaminophen
Gilead Provides An Update: Review And Analysis Of Wednesday's Q&A
September Issue of HCV Next
FDA Grants Fast Track Designation to Can-Fite's CF102 in the Treatment of Liver Cancer
Clinical Thought - How I Use Resistance Testing to Guide Management of Patients With Chronic Hepatitis C
Redoing the Math: New York State Revises Its Estimate of People With HIV
Liver injury is associated with mortality in sickle cell disease
Benitec Initiates a Fourth Site in Hepatitis C Clinical Trial
Lack of Health Insurance Limits the Benefits of HCV Screening
HCV Fall Newsletters: The Cure - Priceless
Treating Patients With Genotype 3 HCV Infection
What's Next in the Hepatitis C Drug Pipeline
The latest patent application of Hepatitis C drug Sovaldi of Gilead is rejected in China
New hepatitis C strategy working, says health minister
Veterans' health care: a call of duty
Sovaldi/ribavirin yields high SVR for Egyptians with HCV genotype 4
Watermelon Benefits for Hepatitis C and Liver Cirrhosis
Hepatitis B and C: Double Trouble for Your Liver
International Conference on Viral Hepatitis Postponed
All you need to know about testing for Hepatitis C
Vancouver’s Downtown Eastside: Psychosis and hepatitis C-related liver dysfunction associated with increased mortality
Hepatitis C Genotype 3 - Updated Label for Daklinza (daclatasvir) Approved by the European Commission
Big Pharma's Foe Takes Victory Lap as Drug Price Increases Slow
Olysio/Sovaldi combination yields high SVR12 in Child-Pugh A cirrhosis
Researchers observe upward trend in hepatitis C infection rates among HIV+ men who have sex with men
Do million-dollar medicines deliver enough bang for the buck?
New York attorney general targets devil's claw manufacturers
MODELLING THE HELICASE TO UNDERSTAND HEPATITIS
Interferon-free therapies improve liver function in HCV patients
Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies
Innovative Research Centers Program investigates botanical dietary supplements and other natural products
Heroin: The national epidemic
Free HCV Testing - Chronic Liver Disease Foundation and Walgreens to Launch Hepatitis C Testing Campaign
Video/TWIGH Reports: World Hepatitis Summit from September 2-4 in Glasgow, Scotland
Medicines Patent Pool looks at hepatitis C
Gilead Sciences, Inc. Witnesses Slowdown In Hepatitis C Scripts
Effectiveness of Sofosbuvir-based Regimens in Genotype 1 and 2 Hepatitis C Virus Infection in 4026 U.S. Veterans
Cancer and hepatitis C drugs approved for use on the NHS
Anger at hepatitis C trial with call for money to be spent on cures
New Study - SVR Reduces Liver Mortality & Morbidity by 75% and CVD Hospitaliztion by 30%
TGIF Rewind - Free HCV Helpline With App and Big Questions about Hepatitis C
Webinar: What Soaring Drug Prices Mean for Patients
Therapy for Hepatitis C Genotype 3: Moving Forward
Can vaccination contribute to hepatitis C elimination efforts? Q+A
Free Helpline and App for Hepatitis C Patients Offer Peer Support and Self ...
Hepatitis C - Fibrosis index based on four factors better predicts advanced fibrosis or cirrhosis than aspartate aminotransferase/platelet ratio index
Putting an end to global health's 'silent killer'
World Hepatitis Summit harnesses global momentum to eliminate viral hepatitis
HCV Advocate September Newsletter
HCV Advocate Eblast: September 1, 2015
What Controls Liver Size?
5 Key Things to Know About Data on Adverse Effects
Ledipasvir-sofosbuvir plus ribavirin in advanced HCV does well
Meta-analysis- SVR and its Treatment Predictors in HCV Genotype 4 Compared to Genotypes 1, 2, and 3
Hepatitis C screening push focuses on boomers, IV drug users
Costly Hepatitis C Drugs for Everyone?
Probiotics before liver transplantation reduces infections
Articles in Press - Liver Toxicity Associated with Sofosbuvir, an NS5A Inhibitor and Ribavirin Use
Hepatitis C responsible for more liver damage than estimated
Patients With Renal Disease: One of the Remaining Challenges in HCV Therapy
TGIF HCV Rewind: A Week In Review With A Spotlight On Don Crocock and Greg Jefferys
Health ministry approves new hepatitis C drug under insurance scheme
Cytokines influence impaired cognitive function in children with HCV
A new virus in liver cancer
Seattle Children’s Bellevue clinic warns of potential infection risk
One in Four Hepatitis C Patients Denied Initial Approval for Drug Treatment
Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade
Fatty Liver and Diabetes Increase Liver Fibrosis Risk
Wider Reach Is Sought for Costly New Hepatitis C Treatments
Hepatitis C treatment: Back to the warehouse
Interferon-free regimens for the treatment of hepatitis C virus in liver transplant candidates or recipients
HCV Treatment: What Can I Do Now? What's Coming Next?
Surprising Updates to the HCV Guidelines
LT recipient characteristics predict worse outcomes after transplant
Researchers find survival increased over time for patients with cirrhosis admitted to ICU
Hepatitis C finally given approval in United Kingdom after 'inexcusable wait'
Cure Hep C and You May See Your Liver Health Improve
Potential Need For Repeat Hepatitis C Testing
AASLD/IDSA Update - HCV guidance for Cost, Reimbursement and Cost-Effectiveness Considerations
Drug which cures hepatitis C given the go-ahead by NHS
Significant Rise in Organic Food Recalls Due to Bacterial Contamination
Coffee consumption reduces the risk of gallstone disease
Landmark Developments in Pediatrics: 1995-2015
Medicine in India: Rampant Quackery, Baffling Drug LandscapeFirst of a two-part series
Health Canada approves DAKLINZA™ (daclatasvir) for the treatment of chronic Hepatitis C infection across multiple genotypes including genotype 3
Health Canada approves Daklinza for HCV
HCV: The Best Cure Possible or the Best Possible Cure?
Bad News for Hepatitis C Patients: Your Treatment Costs May Be Higher Than Expected
Liver Biopsies Miss 75 % of Hep C-Related Cirrhosis Cases
“Cowboy Doctors” and Health Costs
Vital Therapies crashes after liver therapy fails trial
Hepatitis C sufferer imports life-saving drugs from India, takes on global pharmaceutical company
How to pay the bill for hepatitis C
Poll: Americans want government to bring down prescription drug prices
The epidemiology of cirrhosis in the USA
Causes of death in people with liver cirrhosis
Your Good Health: Hep C curable, but cirrhosis irreversible
Latest News on Hepatitis C Cures
While Washington Tackles Opioid Abuse Epidemic, Hepatitis C Treatment Remains Unaffordable
Hepatitis C - Liver Damage Significantly Underestimated and Underreported
Expression of a single gene lets scientists easily grow hepatitis C virus in the lab
Can we Reduce Muscle Cramps in Patients with Cirrhosis?
High Cost Of Diabetes Drugs Often Goes Overlooked
Lack of health insurance limits the benefits of Hepatitis C virus screening
FDA warns makers of superbug-prone devices over testing violations
News and Views: Recent Approval Holds Promise for Genotype 3, but Hurdles Anticipated
Hepatitis C patients in England denied lifesaving liver drug
HCV Advocate Mid-Month Newsletter
Hepatitis C infection may fuel heart risk
Key Management Decisions in HCV - Case-based Video Presentation Led By Ira M. Jacobson, MD.
SVR leads to survival benefit among HCV patients
Tx Options for HCV GT 1 or 4 Non-responders
A Study of Health-related Quality of Life - Interferon Plus Ribavirin to Interferon- and Ribavirin-free HCV Regimens
New breath test shows possible biomarker for early-stage liver disease diagnosis
New HCV Drugs Cost-effective but Costly: Now What?
Once Disparaged, 'Me-Too' Drugs Crucial For Lower Costs Of Cholesterol, Hepatitis C And Cancer Drugs
Cirrhosis and decompensation are common among people with chronic hepatitis C
Hepatitis C is 'silent epidemic'
Bing To Warn Searchers Of Fake Online Pharmacies
to deliver curative treatment to all patients with hepatitis C
Coffee reduces the risk of hepatic fibrosis in Hep C
HOLKIRA PAK/Nova Scotia - ‘Second shot at life’: N.S. government to cover cost of new Hepatitis C drug
Dasabuvir and ombitasvir/paritaprevir/ritonavir: Hint of added benefit in further patients
AASLD/IDSA Guidlines Updated: When and In Whom to Initiate Therapy
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus
Lifestyle modified weight loss reduces NASH
Liver stem cell identified in mice
Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center “real-life” cohort
Endoscopes still contaminated after cleaning, study shows
Advances in Hepatitis C Treatment: At the Crossroads
Harvoni - Resident benefits from new drug that cures hepatitis C
Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States
HCV Drug Wars - So doctors want Congress to force drug prices down? “What we’re fighting is the greed”
The psychological effects of hepatitis C: 'It was a dirty and uneasy feeling and it began to haunt me
Hep C treatment turned me around: Psychological & Behavioral Transformation Related to Hep C Treatment
A Promising Alternative Therapy for Advanced Liver Cancer
August Newsletters: The Cure for Gilead, New drugs, Genotypes, Plus Hepatitis C and Nonalcoholic Fatty Liver Disease
Janssen starts a study to evaluate simeprevir and odalasvir on AL-335 pharmacokinetics
Increased risk of hepatocellular carcinoma in chronic HCV patients with new onset diabetes
Efficacy and Safety of Daclatasvir for Chronic HCV
HCV Reading: Pharmaceutical companies name their price tag for drugs and that’s that.
How I Expect Evolving Options for HCV Therapy Will Affect Posttransplant Management
Post-EASL Update: Is It Time to Use Resistance Testing to Guide HCV Treatment Decisions?
Gilead's Hepatitis C Dominance Unchecked By AbbVie
Gilead Won’t Run Out of Hep C Patients, or Dollars, Anytime Soon
Gilead hepatitis C drugs build road to Japan
Gilead's product sales soar due to Harvoni
HCV Next: HCV In MSM: An Epidemic with a 'Shocking" Lack of Education
Analysis Provides Insight on Negative Predictors of SVR12
Grazoprevir/Elbasvir Shows Excellent Activity in Prior Non- Responders
WHO Releases 2015 Essential Medicines List, Including HCV Drugs
Daklinza (daclatasvir) in Combination with Sofosbuvir for HCV Genotype 3
TECHNIVIE, a fixed-dose combination containing ombitasvir, paritaprevir, and ritonavir in combination with ribavirin for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis.
Approved Treatments for Hepatitis C updated to include
Daklinza and TECHNIVIE
NICE issues appraisal consultation documents for three new hepatitis C therapies
FDA Acceptance of NDA for Merck's Grazoprevir/Elbasvir Treatment of Hepatitis C Genotypes 1, 4 and 6 Infection
House to Vote on Emergency Bill to Fund Veterans Affairs Department
Dr Marcus Dorner - where are we in the treatment of viral hepatitis?
Health Department issues advisory about Hepatitis C increase
Mark World Hepatitis Day: Test Baby Boomers for Hepatitis C
GPs urged to boost Hep C knowledge
Merck tops Street 2Q forecasts despite lower sales, profit
AbbVie: Viekira Pak Sales Not Likely To Hit $3 Billion Run Rate By Year End
Genotype in Hepatitis C Determines Treatment Course/Genotype 1 is Common with Increasingly Effective Treatment
Gilead's Greed that Kills
Pricey drugs become more affordable - The News Journal
Countdown to World Hepatitis Day: 28th July 2015
News - Viral hepatitis: testing saves lives - ECDC
New hepatitis C drug approved for Quebec's sickest patients
Cape Breton Hepatitis C rates some of the highest in Canada - Nova Scotia ...
Cost keeps cure out of reach for those with Hepatitis C
Women who lost three brothers to NHS blood scandal angry at 'cruel ...
Online symptom-checkers are often wrong
FDA Hepatitis Update - Approval of Daklinza in Combination with Sofosbuvir for HCV Genotype 3 Infection
FDA Hepatitis Update - Approval of AbbVie's Technivie (ombitasvir, paritaprevir, ritonavir) w-ribavirin to treat HCV genotype 4
Medivir announces Janssen submitted supplemental NDA to U.S. FDA for OLYSIO® (simeprevir) in combination with sofosbuvir
FDA Clears Two New Oral Drugs for Hepatitis C
Two DAA regimen in cirrhotic HCV GT1b patients
July Hepatitis Newsletters; Liver disease in menopause, Addressing the Restricted Use of DAA therapies and More...
New Treatment Cures Hepatitis C - Pills Are ‘Revolutionary,’ Liver Expert Says
CDC Underestimates Number of Acute HCV Infections
Underascertainment of Acute Hepatitis C Virus Infections in the U.S. Surveillance System: A Case Series and Chart Review - Opinion
Gastroenterological Society of Australia GESA-ALA
Hepatitis C - Rise in heroin use drives needle exchange programs
Researchers develop world's most sensitive test to detect and ...
Two Current Fronts of the American Health Care Wars: Hepatitis C and Cancer
Medical Marijuana: Where's the Evidence?
TGIF- July Weekly Rewind of Hepatitis C News And Updates Around The Web
Gilead's Harvoni® Approved By Japan's Ministry of Health
Sanofi and Gilead set sail to Japan with new approvals for Toujeo, Harvoni
Must Watch: HCV Virtual Patient - Cases 1-4 are now available
Ledipasvir/sofosbuvir : New Hepatitis C Treatment Needs No Antiviral Boost
Sofosbuvir-Based Regimens Are Associated With High SVR Rates Across Genotypes and Among Patients With Multiple Negative Predictive Factors
Art of Aging: Testing baby boomers for Hepatitis C
Manufacturing deal wins China cheap supply of GSK's new HIV drug
Genotype 3 Report - Treatment history, 3 Guidelines (EASL, UK, AASLD/IDSA/IAS), prevalence, after disease progression
Bangladesh's Beximco launches copy of Sovaldi
Vietnam era veteran carries battle cry of hepatitis C
Hepatitis C reports only ‘tip of iceberg’
Most U.S. Hepatitis C Infections May Be Missed: Study
What's behind fatigue, elevated liver enzymes?
Direct-Acting Antivirals Cure Innate Immunity in Chronic Hepatitis C - EDITORIAL ......"Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function"
Sydney dentist scare: Hygiene breaches put 11,000 people at risk of HIV and hepatitis
Exposure to nature helps quash depression – so enjoy the great outdoors!
The bio-imaging artist
Holkira Pak : With Provincial Approval Ottawa Doctor Is Expecting To Cure Thousands Of His Patients
Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States
Veterans Administration Ending Hepatitis C Treatments
New Analysis Reveals High-Priced Hepatitis C Drugs Could Have Costly Impact on State
FDA Releases Dozens of New Bioequivalence Recommendations, Including for Sovaldi
Physicians should educate pts about medical marijuana to ensure appropriate use and benefits
When Hepatitis C Drapes Us in Shame - Matt Starr
Intradermal HBV Vaccine Appears Safe, Effective for Intramuscular Nonresponders
Hepatitis C Treatment and Injection Drug Users: It Is Time to Separate Fact From Fiction
Alisporivir plus ribavirin, interferon-free or in combination with peg-interferon, for HCV genotype 2 or 3 infection.
State restrictions for hepatitis C drug may go too far
FDA is Sued by Advocacy Groups That Want Gilead Hepatitis C Trial Data
Public Health Groups Sue FDA For Disclosure of Clinical Trial Data for Costly Hep C Drugs
AbbVie's HOLKIRA™ PAK Now Reimbursed in Ontario
Researchers say method to detect drug resistant hepatitis C virus mutants has been developed
Sisi announces Free Treatment for Military Personnel with Hepatitis C
Galectin Therapeutics Initiates Enrollment for GR-MD-02 Phase 2 Clinical Trial in NASH with Cirrhosis
Trans Indie Rocker Isley Reust: I Finally Feel 'Happy to Be the Woman' I Am
Hepatitis C Treatment, the Flu, and the Media
Hepatitis C Treatment and Drug Interactions
Weekend Reading - Natural history of hepatitis C: An Updated Look at the Rate of Progression to Cirrhosis and the Incidence of Decompensation
Obstructive sleep apnea is associated with liver disease: a population-based cohort study.
Health officer may declare HIV, hepatitis C epidemic in Clark County
HCV TGIF Rewind - Peak body, Gilead welcome hepatitis report
Public Health Groups Sue FDA For Disclosure of Clinical Trial Data for Costly Hep C Drugs
Viekira Pak - AbbVie hepatitis C cocktail succeeds in late-stage study
Legal Threats to Connecticut Removes HCV Restrictions
California Caps What Patients Pay For Pricey Drugs. Will Other States Follow?
One year after VA scandal, veterans wait to be treated for everything from Hepatitis C to post-traumatic stress
Burman's Specialty Pharmacy shows hepatitis C cure possible while cutting a third of the drug costs
Medication may stop drug and alcohol addiction
VA to outsource care for 180,000 vets with hepatitis C
Newsweek Story Updated-David Kwiatkowski lab tech who is serving 39-years for infecting people with hepatitis C
China rejects patent linked to Gilead hepatitis C drug
Causes of death in people with chronic HBV infection
Successes and Challenges on the Road to Cure Hepatitis C
Increased Overdose Deaths Contribute To Fatal Injury Rates
Hepatitis Australia- Impact that hepatitis C has on those living with the virus
Accessing and Managing Hep C Treatment: Benefits of Working with a Specialty Pharmacy
Hepatitis C: Saving Baby Boomers - Lucinda Porter, RN
Liver function and survival improve after treatment with Viekirax + Exviera regimen
INVESTIGATION: The Inside Story Of The Money, The Activists, And The Cure For Hepatitis C
HCV NEWS TONIGHT - Patient Friendly Video
5 Natural Remedies That Won’t Cure Your Hepatitis C
Noninvasive Assessment of Liver Fibrosis
Grazoprevir/Elbasvi - Merck Submits NDA To FDA For HCV Genotypes 1,4 and 6
DAAS in the Pipeline: What‘s coming?
The DAAS are expensive; how can patients and insurers afford them?
How should patients with HIV treated, especially in the new era of direct-acting agents?
Achillion partners with Janssen to boost hepatitis C pipeline
Now Available! Archived Webinar on Hepatitis C Prevention Opportunities Among People Who Inject Drugs
Questions & Answers: Prevention of sexually transmitted and blood borne infections among older adults
Studies on the epidemiology of hepatitis B and C virus infections are still needed
Variations in paracetamol(acetaminophen)-induced liver failure among European countries
Impact of New Agents: Hepatitis C
ABBVIE - NEW DATA FOR ITS INVESTIGATIONAL HEPATITIS C TREATMENT IN JAPANESE PATIENTS WITH AND WITHOUT CIRRHOSIS
Consumers Sue Anthem for Denying Coverage for a Gilead Hepatitis C Drug
CDC Urges Baby Boomers to Be Tested for Hepatitis C
Cooperation among viral variants helps hepatitis C survive immune system attacks
GlobeImmune, Gilead Hepatitis B drug fails in mid-stage study
Only until June 1st
Free HCV Peer-Reviewed PDF Bonanza!!!
Benitec Biopharma signs manufacturing deal for hepatitis C treatment
Hepatitis C - A Week In Review
ASSOCIATION OF CAFFEINE INTAKE AND LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C
25 years of Hepatitis C
Hep C med imports- Risky and potentially illegal
Some treatments are eight weeks with one or two pills a day. Can it get shorter/easier?
When to Treat: Hepatitis C
Full Text - PDF
Long-term treatment outcomes of patients infected with Hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a Sustained Virological Response
NHS England accused of interference over hepatitis C drug
Hepatitis C: Weighing the Price of a Cure
BEST OF EASL
Watch Expert Perspectives: Best of HCV from EASL 2015
CDC Hepatitis C section Under Fire - "Centers for Disease Control and Prevention: protecting the private good?"
Helping doctors predict what's next for patients diagnosed with Hepatitis C
Cures for other viruses may follow Hep C
Changing the face of hepatitis C management – the design and development of sofosbuvir
FDA Okays Hep-C Investigational Combo for Post-Transplant Patients
Bristol-Myers Squibb Receives Amended U.S. FDA Breakthrough Therapy Designation for Investigational Daclatasvir-based Hepatitis C Regimen
Hep C landscape shifts again as BMS combo nabs breakthrough tag
Dasabuvir in hepatitis C: Indication of added benefit in certain patients
HealthWell Foundation's New Fund Brings Financial Relief to Underinsured People Living with Hepatitis C
MedPage Today HCV HOT TOPICS - 10 Day Video Series
Achillion partners with J&J to develop hepatitis C drugs
High Cost of Hepatitis C Drug Prompts a Call to Void Its Patents
View all updates @ NATAP
EASL: The Impact of Ribavirin on Real World Adherence and Discontinuation Rates in HCV Patients Treated with Sofosbuvir + Simeprevir
Audio - HCV Experienced Patients: Resistance testing, Cirrhosis and Genotype 3 Infection
DDW Daily News - Pricing remains main barrier to HCV eradication
Scientists identify crucial step in helping to prevent Hepatitis C virus replicating
SVR durability using new interferon-free DAAs in comparison to SVR with interferon-based regimens
EASL- Delaying HCV therapy worsens treatment efficacy
Hep C patient sues Blue Cross for blocking access to Harvoni
Lives could be saved with hepatitis C treatment
Hepatitis C Recommendations for 2015 - DDW
DDW2015- Experts to discuss rapidly evolving hepatitis C recommendations
Hepatitis C - Lawsuit Claims Plaintiffs allege Blue Cross withholds Harvoni treatment for financial reasons
Connecticut- Costly Hepatitis C Drugs Sovaldi, Harvoni and Viekira Pak More Accessible To Medicaid Patients
Shortening hepatitis C treatment to 6 weeks effective but not perfect for easier-to-treat patients
Research leads way for noninvasive detection of early stage liver cancer
Fibromyalgia Has Central Nervous System Origins Patients
Doctors urged to take chronic fatigue syndrome more seriously
Blood Test Provides Guide to Personalized Hepatitis C Therapy
Pharm Exec's 2015 Brand of the Year: Sovaldi and Harvoni for Hepatitis C
Hepatitis Testing Day
DDW 2015: Hep C Tx and Microbiome Top Agenda
WHO Guidelines on Naming Diseases are Well-Meaning, Sensible — But Kind of Boring
Genotype 3:One of the Remaining Challenges for Hepatitis C
Variations in liver cancer attributable to hepatitis virus variations
Hepatitis C -- The Long Goodbye
Novel biomarkers may provide guide to personalized hepatitis C therapy
Study investigates the quality of organs from potential donors with HIV
U.S. Sen. Bernie Sanders Asks VA to Break Patents on Gilead and AbbVie Hep C Drugs
Special Interview on HCV: Dr. S. Wiktor of WHO
Noninvasive Liver Assessment: The US Plays Catch-up
The changing landscape of hepatitis C treatment—not ‘can we cure?’ but ‘who should we cure first?’ Is this an ethical approach?
HBV monitoring key for lymphoma patients with resolved hepatitis
Making Hepatitis C Treatment Affordable
A step closer to accessing Harvoni as TGA approves use.
Prostate Cancer Rates Are Higher Among Patients With Hepatitis C
Cognitive dysfunction (brain fog) and hepatitis C
To Study the Prevalence of Impaired Glucose Tolerance in Patients with Hepatitis C Virus Related Chronic Liver Disease
ABT530+ABT493 Pangenotypic in Phase 2B
May Newsletters: Hepatitis Awareness, Treating Genotype 1, Medications and Side Effect Management
WHO adds hepatitis C drugs to essential list, urges lower prices
Screening Program Links Hepatitis C Detection and Care
BMS:Interferon-free therapy daclatasvir, asunaprevir,and beclabuvir clears hepatitis C in 93 percent of patients in trial
JAMA Author Interview: Daclatasvir, Asunaprevir, and Beclabuvir for HCV Genotype 1
Are We Seeing Innovation In The "Me Too" Hep C Space?
Another study confirms detrimental effects of delaying hepatitis C treatment
Gilead’s Gaffe Leads Drugmakers to Pledge More Openness on Price
Egypt opens first factory for locally produced Sovald
Mylan launches hepatitis-C Sovaldi tablets in India
NY City Council Moves to Require Hepatitis Reporting
Relationship between HCV genotype, liver co-morbidities and fibrosis in the French cohort ANRS CO22 HEPATHER
View Slides @ NATAP
Joint Pain a Major Issue in Chronic HCV Infection
High Cure Rates Will Not Curb Hepatitis C, Expert Warns
Sorting out cirrhosis: Mechanisms of non-response to hepatitis C therapy
Interferon-free therapy for hepatitis C: The hurdles amid a golden era
Systematic review with meta-analysis: comparison between therapeutic regimens for paediatric chronic hepatitis C
The Pharmafocus debate: Is the price of new hepatitis C treatments fair?
Hepatitis C virus: Is it time to say goodbye yet?
Gilead - Strong hepatitis C drug sales
Study results promising for hepatitis C patients awaiting or completing liver transplant
Internet symposium:The Advances in Chronic Hepatitis C: Management and Treatment program
HCV-TARGET - Two Regimens Compared in HCV With Decompensated Cirrhosis
All Oral HCV Therapy is Safe and Effective in Patients with Decompensated Cirrhosis: Report from HCV-TARGET
Benitec Doses Fifth Patient And Initiates Additional Trial Site For Hepatitis C Trial
Editorial: A New Vaccine to Prevent Herpes Zoster.
The Value of Survival Benefits from Treating Hepatitis C at Different Fibrosis Stages with All-Oral, Interferon-Free Therapy Relative to 'Watchful Waiting'
Sofosbuvir Plus Ribavirin Provides High Sustained Virological Response at 12 Weeks in Patients With Hepatitis C Virus Genotypes 2 and 3: Presented at EASL
ALL-ORAL 12-WEEK COMBINATION TREATMENT WITH DACLATASVIR AND SOFOSBUVIR IN TREATMENT-EXPERIENCED PATIENTS INFECTED WITH HCV GENOTYPE 3: A SUBANALYSIS OF THE ALLY-3 PHASE 3 STUDY
A Phase 3, randomised, open-label study to evaluate the efficacy and safety of 12 and 8 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTIMIST-1
NS5A RAVs may persist through 96 weeks after ledipasvir therapy
New EASL guidelines prioritise interferon-free hepatitis C treatment
RECOMMENDATIONS ON TREATMENT OF HEPATITIS C 2015
Statins Show Benefit in Hepatitis C Compensated Cirrhosis
Delaying HCV Tx Reduces Likelihood of Eradication
Weekend Reading - EASL Updates and CCO Article:When Should Patients on the Liver Transplant Waitlist Receive HCV Therapy?
Hepatitis C screening essential to help catch patients with advanced liver fibrosis
Interferon Tx Scores in Tough-to-Treat HCV
Geno 2-5: Gilead Results of Sofosbuvir-Based Regimens in Chronic Hepatitis C Patients
Achillion Presents Detailed Clinical Results on ACH-3102 and ACH-3422 at the International Liver Congress
ALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class A or B)
Bristol-Myers says hepatitis C drug combination succeeds in study
ABBVIE PRESENTS LATE-BREAKING, PRELIMINARY PHASE 3B DATA WITH VIEKIRAX® + EXVIERA® IN HCV PATIENTS W-RENAL IMPAIRMENT
Harvoni induces high response rates in genotype 4, 5 HCV
Interferon Tx Scores in Tough-to-Treat HCV Demonized drug performs well in genotype 3 of hepatitis C.
Merck Announces Presentation of Phase 2 Clinical Trial Results of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir at the International Liver Congress™ 2015
U.S. FDA GRANTS PRIORITY REVIEW TO ABBVIE FOR INVESTIGATIONAL, ALL-ORAL, INTERFERON-FREE THERAPY FOR THE TREATMENT OF GENOTYPE 4 CHRONIC HEPATITIS C
EMA recommends avoidance of certain hepatitis C medicines and amiodarone together
Mylan Pharmaceuticals launches generic hepatitis C drug MyHep in India
Patients feel stigma, discrimination when living with hepatitis
Merck’s Hepatitis C Medicines May Challenge Gilead and AbbVie
C-SALT: Child-Pugh B patients responded to grazoprevir/elbasvir
VIDEO: 2DMRE accurately predicts advanced fibrosis in patients with NAFLD
Cancer rates among patients with hepatitis C are increased compared to those not infected
Merck and Gilead square off in battle of the next-next-gen hep C combos
Gilead's Harvoni and Sovaldi Demonstrate Efficacy/Safety with Advanced Liver Disease
SOLAR 2: Harvoni yields high SVR12 in decompensated patients
Gilead Data for Investigational, All-Oral, Pan-Genotypic Three-Drug Regimen of Sofosbuvir, GS-5816 and GS-9857 for Chronic Hepatitis C
Daclatasvir-sofosbuvir treatment highly effective in patients with HCV and HIV co-infection
Janssen announces results for Simeprevir plus Sofosbuvir at The International Liver Congress™ 2015
Exome sequencing found to assist in determining HCC therapy
Gilead uses Georgia as free-drug testbed for hepatitis C elimination
That Gent, Ed -- Over At Pharmalot -- On Gilead's Latest Hep C "Social Experiment Cure" In Former Soviet Nation
A pre-EASL look at the current landscape of ongoing HCV research
Hepatitis infections is associated with greater mortality in hospitalized patients
State panel OKs more hepatitis-C drug buys
Achieving Sustained Virologic Response in Hepatitis C
Be a hero, sign up as an organ donor
Patients hospitalized on weekends risk more falls and infections
New hep C treatment to hit Egyptian market in May
FDA, SillaJen agree to begin phase 3 liver cancer trial
Can-Fite Applies for Orphan Drug Designation in Europe for CF102 in the Treatment of Liver Cancer
No need for bad blood over bad blood
Heroin addiction in older adults on the rise
Adherence during Hep C antiviral treatment regimens
You should you be talking to your doctor about supplements!
FDA Ponders Putting Homeopathy To A Tougher Test
Weekend Reading At Healio: Lifting the Brain Fog: HCV and Depression in the DAA Era
"From non-A/non-B hepatitis to HCV cure"
Hepatitis Newsletters: Preparing For Hepatitis C Treatment
Recruiting Hepatitis C Clinical Trials-Gilead:Ledipasvir/Sofosbuvir And GS-9857 Plus Sofosbuvir/GS-5816
“I am Ready” for Hepatitis C Treatment: New Harvoni TV Commercial
What Could The Mouth, Gut Tell Us About Cirrhosis?
Management of hepatitis C infection before and after liver
World Journal of Gastroenterology-Baishideng
UPMC Hamot & CORE Team Up For National Donate Life Month
Long-term follow-up of successful hepatitis C virus therapy: waning immune responses and disappearance of liver disease are consistent with cure
EASL Hepatitis C Will Share Spotlight This Year at Liver Congress
AFP/ultrasound ameliorates surveillance of HCC
Common heartburn drugs linked to kidney failure in the elderly
Treating hepatitis C: literature update
FDA approved changes to the Olysio (simeprevir) package insert to include two new Warnings and Precautions
Resurgence of hepatitis C in Mass.
"Hepatic Fibrosis: Concept to treatment" Watch Video
AbbVie's Investigational Chronic Hepatitis C Treatment Granted Priority Review in Japan
Shape-shifting molecule tricks viruses into mutating themselves to death
Hep Blogs : Google Hep C by Rick Nash
Caffeinated drinks associated with decreased risk of liver scarring
Treatment of early stage hepatocellular carcinoma
U.S. prescription drug spending rose 13 percent in 2014: IMS report
WHO statement on public reporting of clinical trial results announced
Interferon-free Regimen Effective for Genotype-4 Chronic Hepatitis C
Gilead Sciences, Inc. (GILD) To Rule The Hepatitis C Market In 2015, Outperforming AbbVie Inc (ABBV)
The fatigue impact scale for daily use in patients with hepatitis B virus and hepatitis C virus chronic infections.
SVR after HCV therapy led to long-term clinical cure
Ten year drive to wipe out hepatitis C in Bradford
Intercept Announces New Data in PBC and NASH to be Presented at EASL 2015
Spring Bank Pharmaceuticals to Present HBV and HCV Results with SB 9200 at EASL 2015
HBV-Arrowhead Cleared to Proceed with Multiple Dose Phase 2b Study of ARC-520
Weekend Reading: Expert Commentary On Two Regimens To Treat Cirrhotic HCV GT1 Patients
Beware of Medicrimes, warn Asian pharmaceutical associations
Increased eligibility for treatment of chronic hepatitis C infection with shortened duration of therapy: Implications for access to care and elimination strategies in Canada.
As WHO drafts its global health strategies, a need to reconsider viral hepatitis response
Gilead’s $1,000 Pill Is Hard for States to Swallow
Film puts Hep C in the spotlight
Could An Allergy Drug Treat Hepatitis C?
Merck's Grazoprevir/Elbasvir Gets FDA Breakthrough Designation - New Data to be Presented at The International Liver Congress™ 2015
AbbVie (ABBV) To Present New Data From Hepatitis C Clinical Development Program At The International Liver Congress 2015
Janssen Highlights Hepatitis C Virus Development Program at The International Liver Congress™ 2015
Opposing Views on Gilead Hepatitis C Presentation
Pricing of Drugs and Formulary Placement: Making Sense of Hepatitis C Treatment
A Conversation With Steve Miller, MD: Come in and Talk With Us, Pharma
Challenges, Need for New Therapies Remain in HCC
End-stage liver disease is a concern for people with HIV and hepatitis B or C co-infection
Does FibroScan Accurately Assess Liver Fibrosis?
Quality of care standards appear unmet in patients hospitalized for decompensated cirrhosis
Hepatitis C virus recurrence after liver transplantation: A 10-year evaluation
Benitec Provides Update On Phase I/IIa clinical trial of TT-034 for hepatitis C
States ask U.S. Congress to launch inquiry of herbal supplements
High price of specialty drugs prompts backlash
Antivirals and Extrahepatic Outcomes in Patients With HCV
The Potential Role of Simeprevir for the Treatment of Hepatitis C
WHO Issues Guideline For Manufacturers Of Generic Hepatitis C Medicine
Update-Recruiting Hepatitis C Clinical Trial Daclatasvir/Sofosbuvir/Ribavirin
Cirrhosis better treated without ribavirin/All-oral simeprevir-sofosbuvir beat interferon-based regimen for HCV
Fibroscan vs histology for liver fibrosis analysis
Janssen Therapeutics Announces Support for Organizations Focused on Improving Care and Treatment for People Who Inject Drugs Living with HIV and/or Hepatitis C
New HCV Drugs Cost-effective for Some With Genotypes 2 and 3
Kidney Transplant Success Varies With HIV and HCV Co-Infection
Relationship between gallbladder polyps and fatty liver?
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study
The Cost of a Cure: Medicare Spent $4.5 Billion on New Hepatitis C Drugs Last Year
Medicare Spent $4.5 Billion on New Hepatitis C Drugs Last Year".
Richard Lehman’s journal review—30 March 2015
UnitedHealth's $12.8 Billion Answer To Expensive Prescription Drugs
World first trials for hepatitis C wonder drug in Sydney's maximum security jails
Hepatitis C patients to be re-tested for active virus
UnitedHealth to buy pharmacy benefits manager Catamaran
WCRF - LIVER CANCER REPORT 2015
Regular Coffee Intake Could Prevent Liver Cancer in Alcohol Drinkers
Download Report - LIVER CANCER REPORT 2015
Weekend Reading: Current options for treating HCV genotypes 1-4
Depression rather than liver impairment reduces quality of life in patients with hepatitis C
Gilead’s Sovaldi® for HCV Genotype 2 Approved By Japan’s Ministry of Health, Labour and Welfare
Ministers meet with blood scandal victims to discuss compensation
Weaknesses Discovered in Hepatitis C Strains Could Lead To Targeted Antibody Vaccine, According To New Study
Lack of insurance bars some from hepatitis C treatment
Our Readers Say: Cost of prescription drugs determined by price or policy?
Using Ledipasvir/Sofosbuvir in Cirrhotic, Treatment-Experienced GT1 Patients: 12 Weeks With Ribavirin or 24 Weeks Without?
Hepatitis C Patient Advocates Speak Out
In His Own Words-Today things are significantly different for people with hepatitis C
Multiple Canadian Provinces to Provide Public Funding for Gilead's Harvoni™
Canadian Liver Foundation Applauds Provinces on Providing Access to Interferon-Free Therapy for Hepatitis C Patients
HCV & Women
March 24 2015
From HCV Advocate
Benitec Biopharma Doses Fourth Patient In Hepatitis C Trial
Fibrosis progression in NAFLD vs NASH
Gilead Sciences, Inc. Issues Warning After Hepatitis Patient Taking Heart Drug Dies
Bristol-Myers Squibb and ZAI Lab Enter Licensing Agreement to Develop, Manufacture and Commercialize Brivanib in China
Dr Reddy's partners Hetero to sell Hepatitis C drug in India
FDA Update - Important safety information: Harvoni , and Sovaldi
HCV therapy found cost-effective in patient with severe liver disease
Hepatitis C - Recent Clinical Data
Gilead Sciences gathering details of buyers of hepatitis-C drug to prevent its diversion
Intercept Announces New Data Analyses From FLINT Trial of Obeticholic Acid in NASH
Editorial - The Lancet
Hepatitis C: only a step away from elimination?
March Issue HCV Next: Chasing the ‘Holy Grail’of Ever-Shortening Regimens
Hepatitis C Lab Tests: Cracking the Code
Olysio/Sovaldi found effective in treating HCV patients with cirrhosis
Predictors of poor mental and physical health in HCV
Australians with Hepatitis C hope new drugs will be approved by Pharmaceutical Benefits Scheme
State health officials see spike in Hepatitis C cases
Diagnostic Performance of Magnetic Resonance Elastography in Staging Liver Fibrosis: A Systematic Review and Meta-analysis of Individual Participant Data
New In March 2015 - HepCBC presents 148 Pages Of Hepatitis C FAQs
Fact sheet: Gilead's chronic hepatitis C treatment restrictions
Charity attacks Gilead over hepatitis C drug restrictions
Surprising Ways Alcohol Affects Your Health – Not Just Your Liver Alcohol can harm multiple organs
Rebooting Cell Programming Can Reverse Liver Failure, Says Children’s Hospital/Pitt Study
HCV Drugs Cost-effective, but Who Should Get Them?
Zydus Cadila launches Gilead’s Hepatitis C drug in India
Bristol-Myers Squibb's Daclatasvir Is Good, But Gilead's GS-5816 Is Better
The Life-Saving Drug that Almost No State Can Afford
Cost-Effectiveness of Novel Regimens for the Treatment of Hepatitis C Virus.
Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United States.
Gilead's Harvoni cost-effective for most patients with HCV
Available treatments for hepatitis C virus cost-effective when initiated early
Prescription drug spending has gone through the roof — and now we know why
Medivir: New Data on Simeprevir Presented at the Conference of the Asian Pacific Association for the Study of the Liver
Interferon-free Treatment of Chronic Hepatitis C With Faldaprevir, Deleobuvir and Ribavirin SOUND-C3, a Phase 2b
Analysts fret over cuts to hep C budget
New market for liver disease spawns race for better testing
New Hepatitis C Drugs: State is advised to cover sickest
Improving Access to HCV Treatment: The Clinician’s Role
Parachute veteran fought for three years to get Hepatitis C treatment through the VA
Specialty drugs save lives, come with daunting price tags
Liver-sparing operation associated with higher survival rates in cancer patients
Bristol-Myers Squibb Announces Acceptance of New Drug Application for Investigational Daclatasvir for FDA Review for the Treatment of Hepatitis C Genotype 3
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)
Natco Pharma gets nod to sell Hepatitis C medicine in India
HCV RNA Does Not Always Mean Treatment Failure
WHO issues its first hepatitis B treatment guidelines
Benitec Biopharma Doses Fourth Patient In Hepatitis C Trial
Finding Strengths and Weaknesses in Hepatitis C's Armor
Future Treatment May Be Best for Kids with Hepatitis C
Hepatitis C: Asunaprevir/Daclatasvir National Patient Consultation Webinar
Expensive new hepatitis C therapies drive prescription-drug cost
Cellular scissors chop up HIV virus
$10 copy of Gilead’s blockbuster Sovaldi appears in Bangladesh
Barriers to HCV Treatment in the Era of Triple Therapy
Natco Pharma up 4%, launches hepatitis C drug in Nepal
Screening for Zinc Deficiency in Patients with Cirrhosis: When Should We Start?
Hundreds of D.C. residents to get access to world’s most expensive drug
Experts Discuss: Cost-Based Treatment Decisions,Comparing Adverse Events of HCV Drugs And More...
What to Eat When You Have Hepatitis C
Islet Sciences, Inc. Confirms Issuance of U.S. Patent for Using SGLT2 Inhibitors to Treat NASH/NAFLD
HCV March Newsletters: Children with Hepatitis C, Cirrhosis, Cure, Cost Of Treatment and More
Clinical Liver Disease - New Treatments for Hepatitis C
Hepatitis C Virus Treatment on an Individual Basis
State OKs new Hep C drug for Medicaid patients
Ending an Epidemic: Overcoming the Barriers to an HCV Free Future
Born Between 1945-1965? Get Tested for Hepatitis C
Sovaldi - Attacking the Patent System for Pricing Issues Is a Non-Starter
Progression to severe fibrosis or cirrhosis is common among baby boomers with hepatitis C in the US
Gilead's Harvoni gains NICE yes - but won't face funding delay - genotype 1, 4 , but not genotype 3
Gilead, Hepatitis C Drug Prices and More!!
MUMBAI-Natco Pharma ties up with Gilead on hepatitis C drugs
Delay HCV Tx and Watch Patients Die
Factory making fake Hepatitis C drug raided
Cirrhosis Regression in HCV Patients After Antiviral Therapy
Chronic hepatitis C virus infection and neurological and psychiatric disorders: An overview
Who is on the Liver Transplant Waitlist?
Gilead Announces SVR12 Rates From Phase 3 Study Evaluating Harvoni® for the Treatment of Chronic Hepatitis C in Patients Co-Infected With HIV
Gilead avoids billions in U.S. taxes on its $1,000-a-pill drug
Bristol hep C drug helps cure 97 pct of HIV coinfected patients-study
NICE guidance recommends sofosbuvir (Sovaldi, Gilead Sciences) and simeprevir (Olysio, Janssen) for treating hepatitis C
California Lawmaker Wants Pharma to Reveal Costs for Pricey Drugs
Daclatasvir for hepatitis C: Hint of added benefit in geno 4
Canada - With hep C, no province is an island
How Did A Celibate 82-Year-Old Buddhist Monk Contract HIV
AbbVie study results from VIEKIRA PAK in chronic hepatitis C patients
Findings from Toranomon General Hospital Provides New Data about Antiviral Research (Daclatasvir combined with peginterferon alfa-2a and ribavirin in...
Ciclofilin Pharmaceuticals Granted Patent in Japan for Cyclophilin Inhibitor Drugs
Mylan Signs Exclusive Agreement with Gilead Sciences to Distribute Sovaldi® and Harvoni® in India
Antiviral treatment and extrahepatic outcomes in Hep C
Worldwide treatment of hepatitis C could be within sight at the right cost
Next-Generation HIV and Hep C Treatment Plans Ahead at CROI
Interferon-free Treatment for HCV Genotypes 2 and 3
Severity of liver disease among chronic hepatitis C patients
ABBVIE SUBMITS NEW DRUG APPLICATION IN JAPAN FOR ITS INVESTIGATIONAL, ALL-ORAL, TREATMENT FOR CHRONIC HEPATITIS C
Are sky-high prices for new drugs justified?
The Hepatitis C Scorecard: Gilead is Trouncing AbbVie, but at a Price
$5M Hepatitis C strategy announced by P.E.I. government
Gilead agrees 41,000 eur hep-C drug price for 12 week treatment
Patient-reported outcomes in chronic hepatitis C - the impact of liver disease and new treatment regimens
Promising new hepatitis C drugs come at high cost to state
Shorter Hepatitis C Treatment Durations May Be a Reality
Ledipasvir-Sofosbuvir Effective In Hard-to-Treat HCV
HCV Special Populations And Genotype 3: Still Difficult to Treat?
The FDA is serious about Breakthrough status standing for something
Gilead expects big increase in Europeans treated with hep C drug
SVR lowers all-cause mortality in hepatitis C patients
Gilead faces challenge to European patent on pricey hep C drug
Achillion, Gilead drug cocktail cures hepatitis C in six weeks
Regulus' Dream of a Single-Shot Hepatitis C Cure Falls Short
All HCV Patients Treated with a Single SC Administration of 4 mg/kg of RG-101 Responded with Mean Viral Load Reduction of 4.8 log10 at Day 29 and 9/14 Patients are Below the Limit of Quantification at Day 57
Worldwide treatment of hepatitis C could be within sight at the right cost
Genotype 1-4: Optimal Interferon-free Therapy in Treatment-experienced Chronic Hepatitis C Patients
February Newsletters: HCV Treatment, Research, Forums and More
Threefold increase in cirrhosis risk with HCV
Advances in hepatitis C treatment. Why aren’t they being used?
Strategies for Slowing the Progression of Liver Fibrosis in Hepatitis C
HCV Drug Pipeline Updated
Cigna signs agreement with Gilead To include Harvoni as Preferred Treatment for Hepatitis C Genotype 1
Rolling out hepatitis C treatments will be costly | Editorial
What the ‘Shocking’ Gilead Discounts on its Hepatitis C Drugs Will Mean
Liver Fibrosis Starts Early After Hepatitis C Infection
Hepatitis C - Merck said FDA intends to rescind its "breakthrough therapy" designation
Sales of Sovaldi, New Gilead Hepatitis C Drug, Soar to $ 10.3 Billion
Hepatitis Quest Moves From C to B Under Former Gilead Executives
Drug-drug Interaction Profile of the All-Oral Anti-Hepatitis C Virus Regimen of Paritaprevir/Ritonavir, Ombitasvir and Dasabuvir.
Scientists discover viral 'Enigma machine'
Catamaran Selects Gilead Sciences as its Exclusive Hepatitis C Treatment Provider
Liver cancer Australia's most deadly cancer
Testosterone in men with advanced liver disease
Transparency in clinical trials: The importance of getting the whole picture
How Hepatitis C Is Shining A Light On Critical Gaps In Payment Reform
All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase 3 Study
Daclatasvir in Spain
Daclatasvir EMA Summary of Product Characteristics/Label
More patent-opposition on Gilead’s hepatitis C drug, sofosbuvir
IFN-free Therapy in Treatment-naive Patients With HCV
AbbVie Announces Top-line Results from Phase 3 Study of All-Oral Treatment for Hepatitis C in Japan
Video Weekend-Dr. Galati On New HCV Treatments: Sovaldi, Harvoni, Olysio, and Viekira Pak
Low Salt Diet in Cirrhosis and Liver Disease: Advise to Patients and Family
Weekend Reading - Patient Friendly Audio discussing interferon-free regimens for the treatment of HCV
Hepatitis C Scorecard: Express Scripts Drafts Inferior Drug —Express Scripts' peers choose Harvoni/Solvadi over Viekira Pak.
Intercept Receives Breakthrough Therapy Designation From FDA for Obeticholic Acid for Nonalcoholic Steatohepatitis (NASH) With Liver Fibrosis
UnitedHealth backs Gilead's Harvoni as preferred hepatitis C treatment
New Hepatitis C drug will save Missouri 4.2 Million Dollars
PBM EnvisionRx chooses Gilead hepatitis C drugs for its formulary
Quest in broad deal with CDC for hepatitis analysis
Current and Future HCV Therapy-Do We Still Need Other Anti-HCV Drugs?
Gilead Expands Hepatitis C Generic Licensing Agreements to Include Investigational Pan-Genotypic Agent
Gilead to Allow Generic-Drug Makers to Produce New Hepatitis C Treatment
How Your Drinking Patterns May Affect Your Liver
HCV Weekend Video - Basic facts on hepatitis C
Sofosbuvir-based regimens for HCV: SVR12 Is Equivalent to SVR24 in Assessing New HCV Regimens
German insurers win discounts on Gilead's Sovaldi
Key role for Hep C Inquiry
NEW REVOLUTIONARY CULTURING TECHNIQUE FOR LIVER AND PANCREAS
Express Scripts' Miller says hepatitis C price war to save billions
Researchers unravel complicated relationship between diabetes and HCV
New machine-perfusion organ preservation system keeps livers healthier for transplant
Woman Cured Of Hepatitis C Credits New Drugs
Hepatitis C Infection Treatment Will Be Discontinued
Hepatitis C - Benefits firms shouldn't play drug favorites: CEO
Opposition to HCV Screening Raises a Few Interesting Points — But Has Some Really Wacky “Facts”
HCV Next: HCV FORECAST 2015: New Approvals, Continued Barriers to Care
AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir) and EXVIERA® (dasabuvir) Licensed for Use in the UK for the Treatment of Chronic Hepatitis C
HCV NEXT @ Healio January Issue
2014 Drug Approvals: Where We Have Been; Where We Are Going
Aetna backs Gilead's hepatitis C treatment and gets discount
AbbVie Strikes Hepatitis C Discount Deal With AIDS Drug Programs
AbbVie’s hepatitis C drug Viekirax gets European approval
TGIF - Review of this weeks top hepatitis C headlines
NICE backs new hepatitis C treatments
AGA Perspectives - Who Should Treat Hep C?
Gilead Denied Patent for Hepatitis C Drug Sofosbuvir in India
Hepatitis C Drugs Show Patients Benefit Most From Treatment Choices
Aetna CEO says no decision yet on how to cover hepatitis C drugs
Gilead, AbbVie Hit By Fresh Concerns On Hep C Discounting
2015 - Liver Health News and Research
High hepatitis C cure rate seen in trial of 6-week oral drug regimens
UPDATE: Gilead (GILD), AbbVie (ABBV) Hep. C Drugs Both Given Prefered Status at Prime
Hepatitis Drug Prices Fall So Low, No Exclusives Needed
Alisporivir program rights returned to Debiopharm
Harvoni versus Olysio & Sovaldi versus Viekira Pak
Brown's Budget Proposal Allocates Millions For Hepatitis C Drugs
Merck Accelerates Drug-Submission for hepatitis C and lung cancer
Express Scripts and CVS Exclusivity Deals: Immediate Cost Savings Overshadow Long-Term Medical Concerns
Hepatitis C Update-Treatment Of Genotypes 1,2,3,4,5,and 6
Anthem selects Gilead as primary supplier of hepatitis C drugs
At $594 Per Dose Gilead Sciences, Inc. (GILD) Hepatitis Drug Is Too Costly For Veterans Affairs Department
2015 HCV Newsletters: The Price Wars, The Good News and Hope
Afternoon HCV News Ticker:
Benitec Advances Hepatitis C Clinical Trial
Interview WSJ: Express Scripts Talks About AbbVie Hepatitis C Drug Deal
Gilead Sciences Announces Acquisition of Phenex Pharmaceuticals’ Development Program for Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases
Gilead exclusive provider of hepatitis C medicine for CVS
Patient Advocate Foundation Offers New CareLine for Hepatitis C Patients
Drug pricing concerns? Not at Gilead
Is there a balm for Gilead?
Liver Cirrhosis More Common Than Previously Thought, Study Finds
New drugs offer hope, barriers for hepatitis C patients
Newer Treatment Paradigms for Chronic Hepatitis C
Hepatic Encephalopathy Symptoms